SIGA Technologies Stock: Means To Address Monkeypox Outbreak (NASDAQ:SIGA)
seekingalpha.com
finance
2022-05-27 16:22:38

D-Keine/E+ via Getty Images Investment Thesis SIGA Technologies (NASDAQ:SIGA) shares have risen in value from ~$7, to $11 across the past month - a gain of 57%. The key catalyst for this $700m market cap biotech was the approval - announced on May 19th - of an intravenous formulation of its TPOXX therapy indicated for treatment of smallpox - although it is hard to ignore a second potential value driver - the outbreak of the Monkeypox virus in non-endemic countries. SIGA's core business has been the provision of oral TPOXX to the US Government, which has proven profitable and marks the biotech out as an interesting investment opportunity, but with these 2 new catalysts in play, the ante has been upped slightly, and the question for investors to answer is whether SIGA stock is now worth paying the premium for.
